Clinical Trial Update: Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab

View source ↗

Summary

A clinical-trial update presenting real-world data on using the immune-checkpoint inhibitor tislelizumab to treat lung cancer, with recruiting sites led by IKF …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Conditions: Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC) | Status: RECRUITING